The revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI) can be used to assess disease activity and damage. Acute cutaneous LE affects at least 50% of patients with systemic lupus erythematosus (SLE). Specific features of acute cutaneous LE may include: See more images of systemic lupus erythematosus. Any side effects from stopping plaquenil Hydroxychloroquine 200 mg中文 Plaquenil peak Side effects stopping plaquenil It can reduce skin problems in lupus and prevent swelling/pain in arthritis, though it is not known exactly how the drug works. How to use Plaquenil Hydroxychloroquine is usually taken with food. The antimalarial agents chloroquine CQ and hydroxychloroquine HCQ are considered to be effective for the treatment of cutaneous lupus erythematosus CLE and the symptoms associated with systemic lupus erythematosus SLE such as rashes, joint pain, and fatigue. Aug 07, 2018 Subacute cutaneous lupus erythematosus SCLE is a nonscarring, non–atrophy-producing, photosensitive dermatosis. SCLE commonly develops in sun-exposed areas, including the upper back, shoulders, extensor arms, neck, and upper torso, while the face is often spared. One-third of the cases are due to previous drug exposure. About 15% of patients with cutaneous LE have subacute cutaneous LE. Plaquenil for cutaneous lupus Plaquenil Uses, Dosage & Side Effects -, Effects of Hydroxychloroquine in Patients With Cutaneous. Hydroxychloroquine hibiscus teaPlaquenil stoppingHydroxychloroquine mechanism of action sle Hydroxychloroquine Plaquenil is used to treat malaria, lupus, and rheumatoid arthritis. Learn about side effects, warnings, dosage, and more. Hydroxychloroquine Side Effects, Dosage, Uses, and More. Subacute Cutaneous Lupus Erythematosus SCLE Medication.. Plaquenil Hydroxychloroquine - Side Effects, Dosage, Interactions - Drugs. Cutaneous lupus erythematosus, including subacute cutaneous lupus, is an autoimmune disease felt to be due to an interplay of genetics, hormones and environment. Given that lupus is more common in women of childbearing age, estrogen is felt to contribute to the disease pathogenesis. TreatmentRisksClinical significanceContraindicationsPreventionResultsBenefitsPrognosis Cutaneous lupus erythematosus CLE is the second most common presenting symptom of autoimmune lupus erythematosus LE. Lesions precede the onset of systemic symptoms in 25 percent of patients, many of whom present to dermatologists for their initial evaluation.1 Prompt diagnosis of CLE requires a thorough understanding of the cutaneous manifestations and clinical spectrum of lupus.